Boris Claude Pasche

Prof. Dr. Boris Claude Pasche

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Cancer Communications
Verified
Journal Article
Open access
AJAllan M. Johansen
Allan M. Johansen
JZJulie T. Ziegler
Julie T. Ziegler
KAKojo Agyemang
Kojo Agyemang
MPMichael J. Pennison
Michael J. Pennison
HJHugo Jimenez
Hugo Jimenez
BPBoris Claude Pasche
Boris Claude Pasche
It is estimated that 20% of 30% of colorectal cancer (CRC) cases are inherited, although the genetic drivers of risk are not well established [1]. Transforming growth factor beta (TGF-β) plays a central role in the development and progression of CRC. TGFBR1*6A (6A) is a common polymorphism of TGFBR1, an in-frame deletion of 3 GCG repeats coding for Alanine (Ala) within the TGFBR1 signal sequence. Wild-type TGFBR1 encodes for 9 Ala (9A) [2]. 6A (rs11466445) is not included in genome-wide association study (GWAS) chips and is commonly missed by next-generation sequencing platforms because of its high content of guanine (G) and cytosine (C) bases, which hamper polymerase chain reaction amplification by formation of secondary structures and the requirement for high melting temperatures. The association of 6A with cancer risk has been investigated in multiple types of cancer, and 6A is part of a haplotype putatively associated with colon cancer risk in humans [3]. The shortcoming of these studies has been the lack of adjustment for genetic ancestry and the investigation of a relatively low number of cases and controls. Here, we report the impact of 6A as a modifier of CRC using a novel knock-in mouse model and extend those findings to humans via a large family-based, case–control study, adjusting for genetic ancestry.